Has Daniel Arzola Castaner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $15,421 in general payments to Daniel Arzola Castaner, MD across 350 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Arzola Castaner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Arzola Castaner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Arzola Castaner, MD

Clinical Cardiac Electrophysiology · Bayamon, PRNPI 1548278187

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,156 of the $15,421 with a category attached, or 65.9%. Medtronic accounts for 63.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $5,302 and has fallen 73.6% since, to $1,401 in 2025. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in PR, where the typical reported total is $31,516.

$15,421in general payments, 2019–2025

Across 350 payments — averaging $44.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$10K
Abbott$5K
Boston Scientific$416
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$320
Johnson And Johnson International$85
Johnson & Johnson$61
plus $78 from 4 others

What the payments were for

Consulting fees$2,75018%
Travel & lodging$2,51516%
Food & beverage$10,15666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	283	$9,816
Abbott	28	$4,646
Boston Scientific	10	$416
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	18	$320
Johnson And Johnson International	5	$85
Johnson & Johnson	2	$61
Amgen	1	$26
Biotronik Inc.	1	$24
Cardinal Health P.r. 120 Inc	1	$14
E.r. Squibb & Sons, L.L.C.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Ensite Cardiac Mapping System$2,250
Allure CRT Pacemaker$1,826
SelectSecure$584
Micra$486
Amplia MRI$383
COBALT DR MRI SURESCAN$274
AURORA EV-ICD MRI SURESCAN$242
LINQ II$215
CareLink$163
PulseSelect$154
LUX-Dx Insertable Cardiac Monitor$146
DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$136
CryoConsole$125
CLARIA MRI QUAD CRT-D SURESCAN$122
RESONATE EL ICD VR$120
CARDIOBLATE CRYOFLEX$115
ASSURITY$114
AZURE XT DR MRI SURESCAN$105
Claria MRI$102
Consulta$100

How this compares

$15,421 in reported general payments places this provider in the 35th percentile of 22 clinical cardiac electrophysiology providers in Puerto Rico.

See all clinical cardiac electrophysiology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$24,571

Medicare patients

Services billed

318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	113	$76,857
XareltoRivaroxaban	29	$19,996
MultaqDronedarone Hcl	16	$14,305
Metoprolol Succinate	140	$1,856
Flecainide Acetate	55	$1,532
Amiodarone Hcl	33	$433
Verapamil ErVerapamil Hcl	14	$413
Digoxin	23	$355
Metoprolol Tartrate	12	$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonXarelto	$61	$19,99629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 22 clinical cardiac electrophysiology providers in Puerto Rico.

Other clinical cardiac electrophysiology in Bayamon

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →